New drug development in digestive neuroendocrine tumors.
The traditional cytotoxic agents are of limited efficacy in the treatment of neuroendocrine tumors of the gastrointestinal tract (NETs). Recent investigations have brought up a number of biological features in this family of neoplasms that could represent targets for anticancer treatment. NETs seem to have an extraordinary tumor vascularization with high expression of proangiogenic molecules such as the vascular endothelial growth factor along with overexpression of certain tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR), the insulin growth factor receptor (IGFR) and their downstream signaling pathway components (PI3K-AKT-mTOR). The rationale of an antiangiogenic approach in the treatment of NETs and the use of other pharmacological strategies such as EGFR, IGFR and mammalian target of rapamycin inhibitors are discussed. Additionally, the emerging results of recent clinical trials with these targeted drugs are presented.
Durán
I
I
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Canada.
Salazar
R
R
Casanovas
O
O
Arrazubi
V
V
Vilar
E
E
Siu
L L
LL
Yao
J
J
Tabernero
J
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D005770:Gastrointestinal Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D018358:Neuroendocrine Tumors / Q000098:blood supply / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors